• Korean journal of applied entomology
• /
• v.45 no.2 s.143
• /
• pp.217-226
• /
• 2006

As the results achieved by the evaluation of toxicities on an aphid parasitoid, Aphidius colemani by 79 pesticides registered as horticultural pesticide and 4 adjuvants far pest control, 6 insecticides including a-cypermethrin, 13 fungicides including metalaxyl-M+mancozeb and 4 acaricides including bifenazate showed low toxicity against A. colemani adult. Low toxicity was showed in all the 4 adjuvants as well. In residual toxicity test from 40 pesticides which showed toxicity more than 50%, A. colemani was safe from 11 pesticides from the 3th day after treatment, 7 pesticides from the 5th day after treatment and 14 pesticides from the 7th day after treatment, respectively. But, chlorpyrifos-methyl, diflubenzuron+chlorpyrifos, etofenprox+diazinone and imidachloprid+chlorpyrifos showed high toxicities reaching 100%, 97.7%, 100% and 100% respectively, even from the 7th day after treatment. To evaluate the control effect by A. colemani against Myzus persicae in a greenhouse, A. colemani was released at parasitoid versus aphids rates of 1:50 and 1:100 when the population of M persicae was 50 per plant. After release, aphids population remained steady for 20 days after release at the level of around 60 aphids per plant. During the investigation, insecticides fur thrips control and fungicides for powdery mildew control were treated, but didn't affect the mummy forming of A. colemani. It may be suggested from these results that the selected insecticides, fungicides, acaricides and adjuvent could be incorporated into the integrated M. persicae management system with A. colemani on greenhouse cultivation.

• Journal of the korean veterinary medical association
• /
• v.33 no.11
• /
• pp.683-691
• /
• 1997

금세기초부터 갖가지 물질이 vaccine에 가해졌으며, 일정한 처방이 vaccine을 더욱 유효하게 만들기 위해서 고안되고 있다. 많은 선택권에도 불구하고 다만 aluminium 염(鹽)만이 사람용 vaccine adjuvant(면역응답강화물질)로 받아들여지고 있으며, 수의(동물)용 vaccine도 크게 aluminium 염의 사용에 의존하고 있다. 현재 많은 새로운 vaccine들이 개발되고 있으나 vaccine당 구성분의 수를 증가시키고 또한 vaccine 과정에서 요구되는 dose 수를 줄이는 vaccine 접종 schedule을 단순화시키고져 하는 욕구가 대두되고 있다. 이제 더욱 유효한 adjuvant들이 이 욕구를 성취시키기 위해서 요구되는 것이다.

• Journal of Pharmaceutical Investigation
• /
• v.9 no.1
• /
• pp.20-27
• /
• 1979

Furazolidone tablets were made of lactose and corn'starch as adjuvants by compression method. Six formulations were used with variation of lactose and starch contents. Dissolution, disintegration, content unifomity, hardness, and weight variation were examined for furazolidone tablets. Furazolidone tablets showed good results by the ratio of 4 : 1 or 3: 2 (lactose:starch), and the pressure of $2500kg/cm^2$.

• YAKHAK HOEJI
• /
• v.30 no.2
• /
• pp.100-103
• /
• 1986

The second derivative absorption spectra of acetaminophen in commercial tablet forms were measured without prior separation from other pharmaceutical adjuvants. The second derivative spectra of acetaminophen were found to have no influence on the characteristic absorbance band of it. A plot of 25 sets of the ordinate (Z) values with various acetaminophen concentrations mixed in other additives gave a straight line (correlation coefficient, 0.9999) and the slope was 2.901${\times}10^{-2}Z$ value/($\mu\textrm{g}$/ml). The procedures were sufficiently sensitive, precise and economical for the assay of tablets of acetaminophen.

• IMMUNE NETWORK
• /
• v.12 no.5
• /
• pp.165-175
• /
• 2012

Vaccination is one of the most effective methods available to prevent infectious diseases. Mucosa, which are exposed to heavy loads of commensal and pathogenic microorganisms, are one of the first areas where infections are established, and therefore have frontline status in immunity, making mucosa ideal sites for vaccine application. Moreover, vaccination through the mucosal immune system could induce effective systemic immune responses together with mucosal immunity in contrast to parenteral vaccination, which is a poor inducer of effective immunity at mucosal surfaces. Among mucosal vaccines, oral mucosal vaccines have the advantages of ease and low cost of vaccine administration. The oral mucosal immune system, however, is generally recognized as poorly immunogenic due to the frequent induction of tolerance against orally-introduced antigens. Consequently, a prerequisite for successful mucosal vaccination is that the orally introduced antigen should be transported across the mucosal surface into the mucosa-associated lymphoid tissue (MALT). In particular, M cells are responsible for antigen up-take into MALT, and the rapid and effective transcytotic activity of M cells makes them an attractive target for mucosal vaccine delivery, although simple transport of the antigen into M cells does not guarantee the induction of specific immune responses. Consequently, development of mucosal vaccine adjuvants based on an understanding of the biology of M cells has attracted much research interest. Here, we review the characteristics of the oral mucosal immune system and delineate strategies to design effective oral mucosal vaccines with an emphasis on mucosal vaccine adjuvants.

• Plant Biotechnology Reports
• /
• v.4 no.2
• /
• pp.139-148
• /
• 2010

Jatropha curcas L. (Physic nut) is a commercially important non-edible oil seed crop known for its use as an alternate source of biodiesel. In order to investigate the morphogenic potential of immature embryo, explants from four developmental stages were cultured on medium supplemented with combinations of auxins and cytokinins. It was found that the size of embryo is critical for the establishment of callus. Immature embryos (1.1-1.5 cm) obtained from the fruits 6 weeks after pollination showed a good response of morphogenic callus induction (85.7%) and subsequent plant regeneration (70%) with the maximum number of plantlets (4.7/explant) on Murashige and Skoog's (MS) medium supplemented with IBA (0.5 $mg\;l^{-1}$) and BA (1.0 $mg\;l^{-1}$). The above medium when supplemented with growth adjuvants such as 100 $mg\;l^{-1}$ casein hydrolysate + 200 $mg\;l^{-1}$ L-glutamine + 8.0 $mg\;l^{-1}$ $CuSO_4$ resulted in an even higher frequency of callus induction (100%). Plant regeneration (90%) with the maximum number of plantlets (10/explant) was achieved on MS medium supplemented with 500 $mg\;l^{-1}$ polyvinyl pyrrolidone + 30 $mg\;l^{-1}$ citric acid + 1 $mg\;l^{-1}$ BA + 0.5 $mg\;l^{-1}$ Kn + 0.25 $mg\;l^{-1}$ IBA. It was observed that plantlet regeneration could occur either through organogenesis of morphogenic callus or via multiplication of pre-existing meristem in immature embryos. The age of immature embryos and addition of a combination of growth adjuvants to the culture medium appear to be critical for obtaining high regeneration rates. Well-developed shoots rooted on half-halfstrength MS medium supplemented with 0.5 $mg\;l^{-1}$ IBA and 342 $mg\;l^{-1}$ trehalose. The rooted plants after acclimatization were successfully transferred to the field in different agro-climatic zones in India. This protocol has been successfully evaluated on five elite lines of J. curcas.

• Clinical and Experimental Reproductive Medicine
• /
• v.46 no.4
• /
• pp.178-188
• /
• 2019

Objective: To determine the clinical pregnancy (CP) and live birth (LB) rates arising from frozen embryo transfers (FETs) that had been generated under the influence of in vitro fertilization (IVF) adjuvants given to women categorized as poor-prognosis. Methods: A registered, single-center, retrospective study. A total of 1,119 patients with first FETs cycle include 310 patients with poor prognosis (109 treated with growth hormone [GH], (+)GH group vs. 201 treated with dehydroepiandrosterone, (-)GH group) and 809 patients with good prognosis (as control, (-)Adj (Good) group). Results: The poor-prognosis women were significantly older, with a lower ovarian reserve than the (-)Adj (Good) group, and demonstrated lower chances of CP (p< 0.005) and LB (p< 0.005). After adjusting for confounders, the chances of both CP and LB in the (+)GH group were not significantly different from those in the (-)Adj (Good) group, indicating that the poor-prognosis patients given GH had similar outcomes to those with a good prognosis. Furthermore, the likelihood of LB was significantly higher for poor-prognosis women given GH than for those who did not receive GH (p< 0.028). This was further confirmed in age-matched analyses. Conclusion: The embryos cryopreserved from fresh IVF cycles in which adjuvant GH had been administered to women classified as poor-prognosis showed a significant 2.7-fold higher LB rate in subsequent FET cycles than a matched poor-prognosis group. The women with a poor prognosis who were treated with GH had LB outcomes equivalent to those with a good prognosis. We therefore postulate that GH improves some aspect of oocyte quality that confers improved competency for implantation.

• BMB Reports
• /
• v.44 no.11
• /
• pp.758-763
• /
• 2011

Immunostimulatory CpG-DNA targeting TLR9 is one of the most extensively evaluated vaccine adjuvants. Previously, we found that a particular form of natural phosphodiester bond CpG-DNA (PO-ODN) encapsulated in a phosphatidyl-${\beta}$-oleoyl-${\gamma}$-palmitoyl ethanolamine (DOPE) : cholesterol hemisuccinate (CHEMS) (1 : 1 ratio) complex (Lipoplex(O)) is a potent adjuvant. Complexes containing peptide and Lipoplex(O) are extremely useful for B cell epitope screening and antibody production without carriers. Here, we showed that IL-12 production was increased in bone marrow derived dendritic cells in a CpG sequence-dependent manner when PO-ODN was encapsulated in Lipoplex(O), DOTAP or lipofectamine. However, the effects of Lipoplex(O) surpassed those of PO-ODN encapsulated in DOTAP or lipofectamine and also other various forms of liposome-encapsulated CpG-DNA in terms of potency for protein antigen-specific IgG production and Th1- associated IgG2a production. Therefore, Lipoplex(O) may have a unique potent immunoadjuvant activity which can be useful for various applications involving protein antigens as well as peptides.

• Journal of Microbiology and Biotechnology
• /
• v.27 no.11
• /
• pp.2060-2069
• /
• 2017

Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.

• Journal of Veterinary Science
• /
• v.22 no.3
• /
• pp.30.1-30.15
• /
• 2021

Background: New-generation adjuvants for foot-and-mouth disease virus (FMDV) vaccines can improve the efficacy of existing vaccines. Chinese medicinal herb polysaccharide possesses better promoting effects. Objectives: In this study, the aqueous extract from Artemisia rupestris L. (AEAR), an immunoregulatory crude polysaccharide, was utilized as the adjuvant of inactivated FMDV vaccine to explore their immune regulation roles. Methods: The mice in each group were subcutaneously injected with different vaccine formulations containing inactivated FMDV antigen adjuvanted with three doses (low, medium, and high) of AEAR or AEAR with ISA-206 adjuvant for 2 times respectively in 1 and 14 days. The variations of antibody level, lymphocyte count, and cytokine secretion in 14 to 42 days after first vaccination were monitored. Then cytotoxic T lymphocyte (CTL) response and antibody duration were measured after the second vaccination. Results: AEAR significantly induced FMDV-specific antibody titers and lymphocyte activation. AEAR at a medium dose stimulated Th1/Th2-type response through interleukin-4 and interferon-γ secreted by CD4⁺ T cells. Effective T lymphocyte counts were significantly elevated by AEAR. Importantly, the efficient CTL response was remarkably provoked by AEAR. Furthermore, AEAR at a low dose and ISA-206 adjuvant also synergistically promoted immune responses more significantly in immunized mice than those injected with only ISA-206 adjuvant and the stable antibody duration without body weight loss was 6 months. Conclusions: These findings suggested that AEAR had potential utility as a polysaccharide adjuvant for FMDV vaccines.